creatinine \> 1,5 mg% or creatinine-clearance \< 50ml/min
bilirubin \> 2mg/dl
ascites or pleural effusion (\> 500ml)
known hypersensitivity against methotrexate, lomustine, procarbazine, rituximab, leukovorin, or dexamethasone
participation in another clinical trial within the last 30 days prior to the begin or parallel to this study
known or current drug or alcohol abuse
Clareo Health | Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma
